169 related articles for article (PubMed ID: 16034101)
1. CpG-containing oligodeoxynucleotides act through TLR9 to enhance the NK cell cytokine response to antibody-coated tumor cells.
Roda JM; Parihar R; Carson WE
J Immunol; 2005 Aug; 175(3):1619-27. PubMed ID: 16034101
[TBL] [Abstract][Full Text] [Related]
2. CpG oligodeoxynucleotides act as adjuvants that switch on T helper 1 (Th1) immunity.
Chu RS; Targoni OS; Krieg AM; Lehmann PV; Harding CV
J Exp Med; 1997 Nov; 186(10):1623-31. PubMed ID: 9362523
[TBL] [Abstract][Full Text] [Related]
3. Phosphorothioate-modified CpG oligodeoxynucleotide (CpG ODN) induces apoptosis of human hepatocellular carcinoma cells independent of TLR9.
Zhang Y; Lin A; Zhang C; Tian Z; Zhang J
Cancer Immunol Immunother; 2014 Apr; 63(4):357-67. PubMed ID: 24452201
[TBL] [Abstract][Full Text] [Related]
4. A dinucleotide motif in oligonucleotides shows potent immunomodulatory activity and overrides species-specific recognition observed with CpG motif.
Kandimalla ER; Bhagat L; Zhu FG; Yu D; Cong YP; Wang D; Tang JX; Tang JY; Knetter CF; Lien E; Agrawal S
Proc Natl Acad Sci U S A; 2003 Nov; 100(24):14303-8. PubMed ID: 14610275
[TBL] [Abstract][Full Text] [Related]
5. Systemic administration of LPD prepared with CpG oligonucleotides inhibits the growth of established pulmonary metastases by stimulating innate and acquired antitumor immune responses.
Whitmore MM; Li S; Falo L; Huang L
Cancer Immunol Immunother; 2001 Dec; 50(10):503-14. PubMed ID: 11776372
[TBL] [Abstract][Full Text] [Related]
6. Effects of interleukin-18 on natural killer cells: costimulation of activation through Fc receptors for immunoglobulin.
Srivastava S; Pelloso D; Feng H; Voiles L; Lewis D; Haskova Z; Whitacre M; Trulli S; Chen YJ; Toso J; Jonak ZL; Chang HC; Robertson MJ
Cancer Immunol Immunother; 2013 Jun; 62(6):1073-82. PubMed ID: 23604103
[TBL] [Abstract][Full Text] [Related]
7. Encapsulation in liposomal nanoparticles enhances the immunostimulatory, adjuvant and anti-tumor activity of subcutaneously administered CpG ODN.
de Jong S; Chikh G; Sekirov L; Raney S; Semple S; Klimuk S; Yuan N; Hope M; Cullis P; Tam Y
Cancer Immunol Immunother; 2007 Aug; 56(8):1251-64. PubMed ID: 17242927
[TBL] [Abstract][Full Text] [Related]
8. An Open-Label Study of Subcutaneous CpG Oligodeoxynucleotide (PF03512676) in Combination with Trastuzumab in Patients with Metastatic HER2+ Breast Cancer.
Quiroga D; Wesolowski R; Zelinskas S; Pinette A; Benner B; Schwarz E; Savardekar H; Johnson C; Stiff A; Yu L; Macrae E; Lustberg M; Mrozek E; Ramaswamy B; Carson WE
Cancer Control; 2024; 31():10732748241250189. PubMed ID: 38797949
[TBL] [Abstract][Full Text] [Related]
9. Interleukin-12- and gamma interferon-dependent protection against malaria conferred by CpG oligodeoxynucleotide in mice.
Gramzinski RA; Doolan DL; Sedegah M; Davis HL; Krieg AM; Hoffman SL
Infect Immun; 2001 Mar; 69(3):1643-9. PubMed ID: 11179339
[TBL] [Abstract][Full Text] [Related]
10. Increase in tumor size following intratumoral injection of immunostimulatory CpG-containing oligonucleotides in a rat glioma model.
Ginzkey C; Eicker SO; Marget M; Krause J; Brecht S; Westphal M; Hugo HH; Mehdorn HM; Steinmann J; Hamel W
Cancer Immunol Immunother; 2010 Apr; 59(4):541-51. PubMed ID: 19798500
[TBL] [Abstract][Full Text] [Related]
11. Pleiotropic action of CpG-ODN on endothelium and macrophages attenuates angiogenesis through distinct pathways.
Wu J; Su W; Powner MB; Liu J; Copland DA; Fruttiger M; Madeddu P; Dick AD; Liu L
Sci Rep; 2016 Aug; 6():31873. PubMed ID: 27558877
[TBL] [Abstract][Full Text] [Related]
12. Circulating nano-particulate TLR9 agonist scouts out tumor microenvironment to release immunogenic dead tumor cells.
Kitahata Y; Kanuma T; Hayashi M; Kobayashi N; Ozasa K; Kusakabe T; Temizoz B; Kuroda E; Yamaue H; Coban C; Yamamoto T; Kobiyama K; Aoshi T; Ishii KJ
Oncotarget; 2016 Aug; 7(31):48860-48869. PubMed ID: 27384490
[TBL] [Abstract][Full Text] [Related]
13. CpG-Oligodeoxynucleotides activate tyrosinase-related protein 2-specific T lymphocytes but do not lead to a protective tumor-specific memory response.
Sfondrini L; Besusso D; Bronte V; Macino B; Rossini A; Colombo MP; Ménard S; Balsari A
Cancer Immunol Immunother; 2004 Aug; 53(8):697-704. PubMed ID: 15034674
[TBL] [Abstract][Full Text] [Related]
14. Systemic targeting of CpG-ODN to the tumor microenvironment with anti-neu-CpG hybrid molecule and T regulatory cell depletion induces memory responses in BALB-neuT tolerant mice.
Sharma S; Dominguez AL; Manrique SZ; Cavallo F; Sakaguchi S; Lustgarten J
Cancer Res; 2008 Sep; 68(18):7530-40. PubMed ID: 18794141
[TBL] [Abstract][Full Text] [Related]
15. Immunotherapy for lung cancer combining the oligodeoxynucleotides of TLR9 agonist and TGF-β2 inhibitor.
Yao Y; Li J; Qu K; Wang Y; Wang Z; Lu W; Yu Y; Wang L
Cancer Immunol Immunother; 2023 May; 72(5):1103-1120. PubMed ID: 36326892
[TBL] [Abstract][Full Text] [Related]
16. Intranasal treatment with CpG-B oligodeoxynucleotides protects CBA mice from lethal equine herpesvirus 1 challenge by an innate immune response.
Kim SK; Shakya AK; O'Callaghan DJ
Antiviral Res; 2019 Sep; 169():104546. PubMed ID: 31247247
[TBL] [Abstract][Full Text] [Related]
17. Repeated administration of synthetic oligodeoxynucleotides expressing CpG motifs provides long-term protection against bacterial infection.
Klinman DM; Conover J; Coban C
Infect Immun; 1999 Nov; 67(11):5658-63. PubMed ID: 10531213
[TBL] [Abstract][Full Text] [Related]
18. Intranasal prophylaxis with CpG oligodeoxynucleotide can protect against Yersinia pestis infection.
Hickey AJ; Lin JS; Kummer LW; Szaba FM; Duso DK; Tighe M; Parent MA; Smiley ST
Infect Immun; 2013 Jun; 81(6):2123-32. PubMed ID: 23545300
[TBL] [Abstract][Full Text] [Related]
19. Folate-conjugated immunoglobulin targets melanoma tumor cells for NK cell effector functions.
Skinner CC; McMichael EL; Jaime-Ramirez AC; Abrams ZB; Lee RJ; Carson WE
Melanoma Res; 2016 Aug; 26(4):329-37. PubMed ID: 27035691
[TBL] [Abstract][Full Text] [Related]
20. Effect of plasmid backbone modification by different human CpG motifs on the immunogenicity of DNA vaccine vectors.
Coban C; Ishii KJ; Gursel M; Klinman DM; Kumar N
J Leukoc Biol; 2005 Sep; 78(3):647-55. PubMed ID: 15961575
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
